# ARRIVENT BIOPHARMA, INC. (AVBP) · Edgar & Edgarette company card

> Figures from the company's own SEC filings.

SEC CIK 1868279 · fiscal year ended — · 0 audited years read · [page](https://www.pops4.com/boards/company/AVBP) · [JSON](https://www.pops4.com/boards/company/AVBP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | — |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | — |
| Net margin | — |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | — |
| Total equity | — |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures


## Edgarette's reading

The filings carry no annual revenue line Edgarette can read (common for banks and insurers, which report income differently). Nothing weighed, nothing guessed.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-11-09 ([filing](https://www.sec.gov/Archives/edgar/data/1868279/000110465926124484/0001104659-26-124484-index.htm))

## Recent filings

- 10-Q · filed 2026-11-09 · [filing](https://www.sec.gov/Archives/edgar/data/1868279/000110465926124513/0001104659-26-124513-index.htm)
- 8-K · filed 2026-11-09 · 2.02 Results of Operations and Financial Condition; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1868279/000110465926124484/0001104659-26-124484-index.htm)
- 8-K · filed 2026-10-26 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1868279/000110465926118550/0001104659-26-118550-index.htm)
- 8-K · filed 2026-10-19 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/0001104659-26-116736-index.htm)
- 8-K · filed 2026-10-13 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/0001104659-26-115161-index.htm)
- 8-K · filed 2026-10-06 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/0001104659-26-113898-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001868279.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1868279

## Cite

POPS4, Edgar & Edgarette: ARRIVENT BIOPHARMA, INC. (AVBP) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/AVBP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.